Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Ortho McNeil Janssen's oral contraceptive, Ortho Tri-Cyclen® Lo. Shipment of this product, for which Teva's trade name is Tri-Lo Sprintec, has commenced.
« previous1 next »
Disscusion boards licensed and powered by ZoneX v3.3.1 Development supported by LifeForm Inc.
All Rights Reserved by SteadyHealth.com
© 2004 - 2009
This site complies with the HONcode standard for trustworthy health information:
verify here.
